Quick Answer
Grace Therapeutics, Inc. reported Net Income of -$9.57 million for fiscal year 2025.
Grace Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$9.57M | +25.6% |
| 2024 | -$12.85M | +69.7% |
| 2023 | -$42.43M | -332.1% |
| 2022 | -$9.82M | +50.1% |
| 2021 | -$19.68M | +22.9% |
| 2020 | -$25.51M | +35.2% |
| 2019 | -$39.37M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$2.31M | +44.3% | -146.8% |
| September 30, 2025 | -$938.0K | +72.7% | +72.1% |
| June 30, 2025 | -$3.36M | -28.5% | +19.1% |
| December 31, 2024 | -$4.16M | -73.8% | -21.1% |
| September 30, 2024 | -$3.43M | -4.9% | -31.1% |
| June 30, 2024 | -$2.62M | +34.9% | -9.5% |
| December 31, 2023 | -$2.39M | +38.5% | +26.9% |
| September 30, 2023 | -$3.27M | +33.6% | +18.6% |
- Grace Therapeutics, Inc. showed an increase of +25.6% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Grace Therapeutics, Inc.’s net income has grown by 75.7% (from -$39.37 million to -$9.57 million).
- The most recent figure is from Grace Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: